Ulcerative Colitis
-
TREMFYA® (guselkumab) Sustains Clinical and Endoscopic Remission in Ulcerative Colitis Through 3 Years
TREMFYRA® (guselkumab) has shown sustained clinical and endoscopic remission in ulcerative colitis patients over three years. This long-term data highlights the drug’s durability, a key factor in the competitive UC market. As a selective IL-23p19 inhibitor, TREMFYRA® targets inflammation precisely, potentially offering a favorable safety profile for chronic management. These findings strengthen its position as a valuable therapeutic option for moderate to severe UC.
-
Abivax to Present Late-Breaking ABTECT Trial Results and Updated Safety Data
Abivax (ABVX) reported positive Phase 3 ABTECT trial results for obefazimod in ulcerative colitis. A pooled analysis showed a 16.4% placebo-adjusted clinical remission rate at Week 8 with the 50mg dose, meeting the FDA primary endpoint. Trials enrolled a refractory population, including patients who failed advanced therapies or JAK inhibitors. No new safety signals for serious infections or malignancies were reported. Headache and nausea were common adverse events. Analysts believe efficacy in the difficult-to-treat patient group could position obefazimod favorably in the market.
